Pipeline

November 9, 2020

Company	Drug/Device	Medical Condition	Status
COVID-19 Trials and Actions
OncoSec Medical	CORVax12	DNA-encodable vaccine against SARS-CoV-2	IND approved by the FDA
Equillium	itolizumab	hospitalized COVID-19 patients with acute respiratory distress syndrome (ARDS)	IND approved by FDA for phase 3 trial
Symvivo Corporation	bacTRL-spike oral vaccine	prevention of COVID-19	first patient dosed in phase 1 trial
RevImmune	CYT107 (recombinant human Interleukin-7)	patients critically ill with COVID-19	patient enrollment initiated in the U.S. in phase 2 trial
Humanigen	lenzilumab	prevention of cytokine storm in hospitalized patients with COVID-19	first patient dosed in phase 3 trial
Other Trials and Actions
enGene	EG-70	Bacille Calmette-Guerin (BCG)-unresponsive nonmuscle-invasive bladder cancer	IND approved by the FDA
InnoCare Pharma	orelabrutinib	multiple sclerosis	IND approved by the FDA
Neuraly	NLY01	Alzheimer’s disease	IND approved by the FDA
OliX Pharmaceuticals	OLX10010	adjunct therapy to reduce the recurrence of hypertrophic scars after scar revision surgery	IND approved by the FDA
TaiGen Biotechnology	TG-1000	influenza A and B	IND approved by the FDA
Aligos Therapeutics	ALG-000184	chronic hepatitis B virus	first patient dosed in phase 1a/1b trial
BiomX	BX002	inflammatory bowel disease	first patient dosed in phase 1a trial
Synlogic	SYNB8802	enteric hyperoxaluria	first patient dosed in phase 1 trial
MindMed	LSD microdose and experiential doses	anxiety disorders	completion of phase 1 trial
Q32 Bio	ADX-914	autoimmune diseases	first patient dosed in phase 1 trial
ADC Therapeutics	camidanlumab tesirine (ADCT-301) in combination with pembrolizumab	select advanced solid tumors	first patients dosed in combination arm of phase 1b trial
Gritstone Oncology	GRANITE and SLATE (neoantigen-based immunotherapies)	historically cold (or non-immunogenic) tumor types	first patients dosed in phase 2 expansion cohorts of phase 1/2 trials
Rubius Therapeutics	RTX-240	acute myeloid leukemia	first patient dosed in phase 1/2 trial
Novus Therapeutics	AT-1501	amyotrophic lateral sclerosis	first patient enrolled in phase 2a trial
AIVITA Biomedical	AV-GBM-1	glioblastoma	patient dosing complete in phase 2 trial
Amino Technology	PalinGen Flow	adults with chronic ulcers of the lower extremities due to venous stasis or diabetic etiologies	initiation of phase 2 trial
NanOlogy	NanoPac (sterile nanoparticulate paclitaxel) for suspension via intratumoral injection	prostate cancer	first patient enrolled in phase 2 trial
PolyActiva	latanoprost-free-acid sustained-release ocular implant	glaucoma	initiation of phase 2 trial in Australia
Enlivix	Allocetra	sepsis	approval received from the Israeli Ministry of Health for a phase 2b trial
Pfizer	vupanorsen (AKCEA-ANGPTL3-LRx)	patients with elevated nonhigh-density lipoprotein cholesterol (nonHDL-C) and triglycerides	initiation of phase 2b trial
Asieris Pharmaceuticals	APL-1202	nonmuscle-invasive bladder cancer	approval granted by the Center for Drug Evaluation of the China National Medical Products Administration to initiate phase 3 trial
Cerevel Therapeutics	tavapadon	Parkinson’s disease	first patients dosed in three phase 3 trials
Concert Pharmaceuticals	CTP-543	moderate-to-severe alopecia areata	initiation of phase 3 trial
Daiichi Sankyo AstraZeneca	Enhertu (fam-trastuzumab deruxtecan-nxki)	adjuvant therapy in patients with HER2-positive early breast cancer with high risk of disease recurrence who have residual invasive disease in the breast or axillary lymph nodes after receiving neo-adjuvant therapy	initiation of phase 3 trial
GW Pharmaceuticals Greenwich Biosciences	nabiximols	multiple sclerosis-associated spasticity	initiation of phase 3 trial
LianBio	infigratinib	locally advanced or metastatic unresectable cholangiocarcinoma with FGFR2 gene fusions	approval granted by the Center for Drug Evaluation of the China National Medical Products Administration to initiate phase 3 trial
Logic Bio	LB-001	methylmalonic acidemia	Fast-Track designation granted by the FDA
Rafael Pharmaceuticals	CPI-613 (devimistat)	soft tissue sarcoma	Orphan Drug designation granted by the FDA
Boston Scientific	Ranger drug-coated balloon	patients with peripheral artery disease in the superficial femoral artery and proximal popliteal artery	approved by the FDA
Chiesi, USA	Bronchitol (mannitol) inhalation powder	add-on maintenance therapy to improve pulmonary function in cystic fibrosis patients 18 years of age and older	approved by the FDA